RxDoctor Payments Data

David Hiltzik, MD

Otolaryngology · New York, NYNPI 1336262591

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,160 of the $24,860 with a category attached, or 61.0%. Cook Incorporated accounts for 80.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $12,449 and has fallen 83.8% since, to $2,014 in 2025. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,860in general payments, 2019–2025

Across 47 payments — averaging $528.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$20K
  • Aerin Medical Inc.$2K
  • Cook Medical LLC$1K
  • Intersect ENT, Inc.$360
  • Stryker$357
  • Regeneron Healthcare Solutions, Inc.$250
  • plus $583 from 7 others

What the payments were for

  • Consulting fees$6,33025%
  • Speaking & faculty fees$15,16061%
  • Travel & lodging$6913%
  • Food & beverage$2,67911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,860 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$448,821
Medicare patients
596
Services billed
2,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate17$13,738
Mometasone Furoate235$13,692
Ipratropium Bromide324$11,850
Levocetirizine Dihydrochloride897$9,122
Famotidine750$4,890
Azelastine Hcl245$4,411
Pantoprazole Sodium659$4,191
Fluticasone Propionate451$4,173
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth18$2,584
Azelastine-FluticasoneAzelastine/Fluticasone11$1,269
Montelukast Sodium200$1,078
Fluocinolone Acetonide Oil36$1,048
Doxycycline Hyclate63$918
Triamcinolone Acetonide16$767
Ofloxacin18$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$195$13,73817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 otolaryngology providers in New York.

Other otolaryngology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →